Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02791581 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Understanding and Predicting Breast Cancer Events After Treatment

Study acronym: UPBEAT
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion moved earlier from Jul 31, 2034 to Jul 31, 2032 Show 5 more changesShow less
    • Eligibility criteria expanded, about 59 words
    • Secondary endpoints: details revised at 10 of 17 entries
    • Site details revised at 7 of 66 sites
    • Publications: details revised at 5 of 5 entries
    • Study description shortened, about 3 words
  2. Primary completion date: Nov 30, 2025 to Jul 31, 2034v32
  3. Primary completion date: Nov 30, 2024 to Nov 30, 2025v31
  4. Primary completion date: Jan 31, 2024 to Nov 30, 2024v30
  5. Primary completion date: Dec 31, 2023 to Jan 31, 2024v29
Show 27 earlier versionsHide 27 earlier versions
  1. Primary completion date: Sep 30, 2023 to Dec 31, 2023v28
  2. Primary completion date: Sep 2023 to Sep 30, 2023
    • Study completion date: Jul 2034 to Jul 31, 2034
    v27
  3. Primary completion date: Jul 31, 2023 to Sep 2023
    • Study completion date: Jul 31, 2034 to Jul 2034
    v26
  4. 2 versions Re-verified since Sep 20, 2021, no change to tracked fieldsv24-v25
  5. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 1000 to confirmed 403
    • Site details revised at 66 of 66 sites
    v23
  6. Primary completion date: Nov 17, 2021 to Jul 31, 2023
    • Study completion date: Nov 17, 2028 to Jul 31, 2034
    v22
  7. Study sites: 61 to 66v21
  8. Study sites: 54 to 61
    • Eligibility criteria expanded, about 8 words
    v20
  9. Site details revised at 1 of 54 sitesv19
  10. Study sites: 46 to 54
    • Eligibility criteria expanded, about 13 words
    v18
  11. Eligibility criteria expanded, about 17 words
    • Secondary endpoints: 16 to 17
    v17
  12. Study sites: 34 to 46
    • Eligibility criteria expanded, about 2 words
    v16
  13. Secondary endpoints: details revised at 3 of 16 entriesv15
  14. Study sites: 3 to 34
    • Eligibility criteria shortened, about 44 words
    • Secondary endpoints: 11 to 16
    • Study description shortened, about 9 words
    v14
  15. Phase: Not specified to Not applicable
    • Interventions: Assessments (Other), Data Collection (Other), Observational (Other) to Cardiac MRI (Diagnostic Test)
    • Study arms: 3 to 2
    v13
  16. Study sites: 2 to 3v12
  17. Primary completion date: Aug 2019 to Nov 17, 2021
    • Study completion date: Dec 2019 to Nov 17, 2028
    v11
  18. Re-verified, no change to tracked fieldsv10
  19. Collaborators expanded, about 4 wordsv9
  20. Start date: Jul 28, 2017 to Jul 21, 2017v8
  21. Study sites: 1 to 2v7
  22. Study title shortened, about 6 wordsv6
  23. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 2017 to Jul 28, 2017
    • Site details revised
    v5
  24. Re-verified, no change to tracked fieldsv4
  25. Start date: Apr 2017 to Jun 2017v3
  26. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is being done to see if patients receiving chemotherapy for breast cancer affects the heart, the ability to exercise and fatigue when compared to patients who do not have cancer.
Trial Details
NCT Number NCT02791581
Lead Sponsor Wake Forest University Health Sciences
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms, Fatigue
Enrollment 403 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov